[{"orgOrder":0,"company":"Xellsmart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS411","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Xellsmart \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Xellsmart \/ Inapplicable"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS228CN","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xellsmart \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xellsmart \/ Undisclosed"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Allogeneic Induced Pluripotent Stem Cell-Derived Dopaminergic Neural Progenitor Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xellsmart \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Xellsmart \/ Undisclosed"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Xellsmart","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS228","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellsmart \/ Xellsmart","highestDevelopmentStatusID":"8","companyTruncated":"Xellsmart \/ Xellsmart"},{"orgOrder":0,"company":"Xellsmart","sponsor":"Xellsmart","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"XS228","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Xellsmart","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xellsmart \/ Xellsmart","highestDevelopmentStatusID":"8","companyTruncated":"Xellsmart \/ Xellsmart"}]